Step
Action Administer the vaccination. Note: Use your clinical judgement to determine if a longer needle is required (38mm). Use of shorter needle has the potential to deliver the vaccine subcutaneously as opposed to intramuscularly, which has the potential to underdose. For more information on needle length, refer to the Immunisation Handbook.
Administer vaccination
IMAC are creating clarified preparation and administration guidance for this situation, including the importance of priming. MoH will distribute a stock of 38mm 21G needles and is also investigating procuring a supply of 38mm 23G needles for distribution. Once the vaccination is complete the vaccinator or administrative support person must update the consumer’s record in CIR to include:
Record vaccination information in CIR
•
The batch and sub-batch number, e.g. AB1234-567 (the first part is the batch number, the second part is the sub-batch number. These are recorded on the vaccine box.)
•
Details of the injection site and the date and time of the vaccination event.
The consumer must remain on site under observation for at least 15 minutes. If the vaccinator determines it necessary, they may ask the consumer to wait for longer than 15 minutes, for example, if the individual is in a rural or remote area or has a history of anaphylaxis. The vaccinator or site administrator will provide the consumer with a card recording the date/time of their vaccination and the date when they will be expected to receive the second dose of the Pfizer vaccine. Consumer waits 15 minutes in observation area
Note: This vaccination receipt card currently serves as the proof of vaccination and must be provided to the consumer. Please encourage consumers to retain their receipt card and keep it somewhere safe or take a photo of their receipt card. MoH is exploring a digital certificate for proof of vaccination.
The site administrator/vaccinator must record the time of the consumer’s exit from the site in CIR.
Record exit in CIR
9.5.4 Planning for Adverse Events Some consumers may have a history of allergy or hypersensitivity following administration of vaccines or injectable medicines that warrants additional monitoring at the time of receiving their first dose of the vaccine. Similarly, some people have experienced an adverse event after receiving their first dose of the vaccine that warrants clinical monitoring at the time of the second dose.
37 | Version 19.0
